AC
AC Immune S.A.
ACIU · NASDAQ
$2.76 -1.43% (-$0.04)
1M +8.66%
Market Cap CHF 227.5M
P/E Ratio -
Div. Yield -
ROE 99.17%
Bulios Fair Price
$2.99
8.3% upside
Current Price
$2.76
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ACIU is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
10 /100
Expensive P/S 12.99x
P/B 6.47x
P/E N/A
Growth
3 /100
Declining Rev. growth 3.17%
Book val. growth 35.70%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 100.00%
FCF margin 199.63%
Net margin 246.49%
Quality
2 /100
Poor ROIC 86.61%
Asset turnover 0.12x
ROE 99.17%
Debt
54 /100
Moderate Debt/Equity 0.12x
Int. coverage -256.38x
Current ratio 0.93x
Stability
25 /100
Unstable Beta 1.57x
Profitable years 0
Rev. volatility 181.62%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ACIU
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Martin Zügel
Employees
106
Headquarters
Lausanne
Upcoming events
03 NOV
Earnings
Upcoming earnings report